In Vivo assessment of drug efficacy against Mycobacterium abscessus using the embryonic zebrafish test system

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 7, 2014, Pages 4054-4063

  Bernut, Audrey ^a   Le Moigne, Vincent ^c   Lesne, Tiffany ^a   Lutfalla, Georges ^a   Herrmann, Jean Louis ^c   Kremer, Laurent ^a,b  

^a UNIV MONTPELLIER   (France)

^b INSERM   (France)

^c Laboratoire de Microbiologie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOXITIN; CILASTATIN PLUS IMIPENEM; CLARITHROMYCIN; ERYTHROMYCIN; IMIPENEM; ISONIAZID; THIOACETAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL LOAD; BACTERICIDAL ACTIVITY; CFU COUNTING; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; FLUORESCENCE IMAGING; FLUORESCENCE MICROSCOPY; IMAGE ANALYSIS; IMAGE PROCESSING; IMMUNE EVASION; IN VIVO STUDY; MICROSCOPY; MINIMUM INHIBITORY CONCENTRATION; MORPHOTYPE; MYCOBACTERIOSIS; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM ABSCESSUS INFECTION; NONHUMAN; PERSISTENT INFECTION; PRIORITY JOURNAL; TREATMENT DURATION; ZEBRA FISH; ANIMAL; ATYPICAL MYCOBACTERIUM; BAGG ALBINO MOUSE; BRAIN ABSCESS; DRUG COMBINATION; DRUG EFFECTS; LARVA; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOUSE; MULTIDRUG RESISTANCE; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; PROCEDURES;

ANIMALS; BRAIN ABSCESS; CLARITHROMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; IMIPENEM; LARVA; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA; OPTICAL IMAGING; ZEBRAFISH;

EID: 84903154184     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00142-14     Document Type: Article

References (44)

1. Medjahed H, Gaillard JL, Reyrat JM. 2010. Mycobacterium abscessus: a new player in the mycobacterial field. Trends Microbiol. 18:117-123. http://dx.doi.org/10.1016/j.tim.2009.12.007.
2. Petrini B. 2006. Mycobacterium abscessus: an emerging rapid-growing potential pathogen. Apmis 114:319-328. http://dx.doi.org/10.1111/j.1600-0463. 2006.apm-390.x. (Pubitemid 43829421)
3. Roux AL, Catherinot E, Ripoll F, Soismier N, Macheras E, Ravilly S, Bellis G, Vibet MA, Le Roux E, Lemonnier L, Gutierrez C, Vincent V, Fauroux B, Rottman M, Guillemot D, Gaillard JL. 2009. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in France. J. Clin. Microbiol. 47:4124-4128. http://dx.doi.org/10.1128/JCM.01257-09.
4. Sanguinetti M, Ardito F, Fiscarelli E, La Sorda M, D'Argenio P, Ricciotti G, Fadda G. 2001. Fatal pulmonary infection due to multidrug-resistant Mycobacterium abscessus in a patient with cystic fibrosis. J. Clin. Microbiol. 39:816-819. http://dx.doi.org/10.1128/JCM.39.2.816-819.2001. (Pubitemid 32150872)
5. Gilljam M, Schersten H, Silverborn M, Jonsson B, Ericsson Hollsing A. 2010. Lung transplantation in patients with cystic fibrosis and Mycobacterium abscessus infection. J. Cyst. Fibros. 9:272-276. http://dx.doi.org/10.1016/j. jcf.2010.03.008.
6. Aitken ML, Limaye A, Pottinger P, Whimbey E, Goss CH, Tonelli MR, Cangelosi GA, Dirac MA, Olivier KN, Brown-Elliott BA, McNulty S, Wallace RJ, Jr. 2012. Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am. J. Respir. Crit. Care Med. 185:231-232. http://dx.doi.org/10.1164/ajrccm.185.2.231.
7. Wallace RJ, Jr, Brown BA, Griffith DE. 1998. Nosocomial outbreaks/pseudo-outbreaks caused by nontuberculous mycobacteria. Annu. Rev. Microbiol. 52:453-490. http://dx.doi.org/10.1146/annurev.micro.52.1.453. (Pubitemid 28481199)
8. Viana-Niero C, Lima KV, Lopes ML, Rabello MC, Marsola LR, Brilhante VC, Durham AM, Leao SC. 2008. Molecular characterization of Mycobacterium massiliense and Mycobacterium bolletii in isolates collected from outbreaks of infections after laparoscopic surgeries and cosmetic procedures. J. Clin. Microbiol. 46:850-855. http://dx.doi.org/10.1128/JCM.02052-07. (Pubitemid 351379968)
9. Zelazny AM, Root JM, Shea YR, Colombo RE, Shamputa IC, Stock F, Conlan S, McNulty S, Brown-Elliott BA, Wallace RJ, Jr, Olivier KN, Holland SM, Sampaio EP. 2009. Cohort study of molecular identification and typing of Mycobacterium abscessus, Mycobacterium massiliense, and Mycobacterium bolletii. J. Clin. Microbiol. 47:1985-1995. http://dx.doi.org/10.1128/JCM.01688-08.
10. Cullen AR, Cannon CL, Mark EJ, Colin AA. 2000. Mycobacterium abscessus infection in cystic fibrosis. Colonization or infection? Am. J. Respir. Crit. Care Med. 161:641-645. http://dx.doi.org/10.1164/ajrccm.161.2.9903062. (Pubitemid 30129479)
11. Tomashefski JF, Jr, Stern RC, Demko CA, Doershuk CF. 1996. Nontuberculous mycobacteria in cystic fibrosis. An autopsy study. Am. J. Respir. Crit. Care Med. 154:523-528. http://dx.doi.org/10.1164/ajrccm.154.2.8756832. (Pubitemid 26269129)
12. Rodriguez G, Ortegon M, Camargo D, Orozco LC. 1997. Iatrogenic Mycobacterium abscessus infection: histopathology of 71 patients. Br. J. Dermatol. 137:214-218. http://dx.doi.org/10.1046/j.1365-2133.1997.18081891.x. (Pubitemid 27333354)
13. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ, Jr, Winthrop K. 2007. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 175:367-416. http://dx.doi.org/10.1164/rccm. 200604-571ST.
14. Jeon K, Kwon OJ, Lee NY, Kim BJ, Kook YH, Lee SH, Park YK, Kim CK, Koh WJ. 2009. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am. J. Respir. Crit. Care Med. 180:896-902. http://dx.doi.org/10.1164/rccm.200905-0704OC.
15. De Groote MA, Johnson L, Podell B, Brooks E, Basaraba R, Gonzalez-Juarrero M. 2013. GM-CSF knockout mice for preclinical testing of agents with antimicrobial activity against Mycobacterium abscessus. J. Antimicrob. Chemother. 69:1057-1064. http://dx.doi.org/10.1093/jac/dkt451.
16. Lerat I, Cambau E, Roth Dit Bettoni R, Gaillard JL, Jarlier V, Truffot C, Veziris N. 2013. In vivo evaluation of antibiotic activity against Mycobacterium abscessus. J. Infect. Dis. 209:905-912. http://dx.doi.org/10.1093/ infdis/jit614.
17. Lavollay M, Dubee V, Heym B, Herrmann JL, Gaillard JL, Gutmann L, Arthur M, Mainardi JL. 11 November 2013. In vitro activity of cefoxitin and imipenem against Mycobacterium abscessus complex. Clin. Microbiol. Infect. http://dx.doi.org/10.1111/1469-0691.12405.
18. Cortes M, Singh AK, Reyrat JM, Gaillard JL, Nassif X, Herrmann JL. 2011. Conditional gene expression in Mycobacterium abscessus. PLoS One 6:e29306. http://dx.doi.org/10.1371/journal.pone.0029306.
19. Bernut A, Herrmann JL, Kissa K, Dubremetz JF, Gaillard JL, Lutfalla G, Kremer L. 2014. Mycobacterium abscessus cording prevents phagocytosis and promotes abscess formation. Proc. Natl. Acad. Sci. U. S. A. 111:E943-E952. http://dx.doi.org/10.1073/pnas.1321390111.
20. Talati NJ, Rouphael N, Kuppalli K, Franco-Paredes C. 2008. Spectrum of CNS disease caused by rapidly growing mycobacteria. Lancet Infect. Dis. 8:390-398. http://dx.doi.org/10.1016/S1473-3099(08)70127-0. (Pubitemid 351697806)
21. Lee MR, Cheng A, Lee YC, Yang CY, Lai CC, Huang YT, Ho CC, Wang HC, Yu CJ, Hsueh PR. 2011. CNS infections caused by Mycobacterium abscessus complex: clinical features and antimicrobial susceptibilities of isolates. J. Antimicrob. Chemother. 67:222-225. http://dx.doi.org/10.1093/jac/dkr420.
22. Rottman M, Catherinot E, Hochedez P, Emile JF, Casanova JL, Gaillard JL, Soudais C. 2007. Importance of T cells, gamma interferon, and tumor necrosis factor in immune control of the rapid grower Mycobacterium abscessus in C57BL/6 mice. Infect. Immun. 75:5898-5907. http://dx.doi.org/10.1128/IAI.00014-07. (Pubitemid 350207829)
23. Catherinot E, Clarissou J, Etienne G, Ripoll F, Emile JF, Daffe M, Perronne C, Soudais C, Gaillard JL, Rottman M. 2007. Hypervirulence of a rough variant of the Mycobacterium abscessus type strain. Infect. Immun. 75:1055-1058. http://dx.doi.org/10.1128/IAI.00835-06. (Pubitemid 46203473)
24. Woods GL, Brown-Elliott BA, Conville PS, Desmond EP, Hall GS, Lin G, Pfyffer GE, Ridderhof JC, Siddiqi SH, Wallace RJ, Warren NG, Witebsky FG. 2011. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard - second edition. M24-A2. CLSI, Wayne, PA.
25. Lamason RL, Mohideen MA, Mest JR, Wong AC, Norton HL, Aros MC, Jurynec MJ, Mao X, Humphreville VR, Humbert JE, Sinha S, Moore JL, Jagadeeswaran P, Zhao W, Ning G, Makalowska I, McKeigue PM, O'Donnell D, Kittles R, Parra EJ, Mangini NJ, Grunwald DJ, Shriver MD, Canfield VA, Cheng KC. 2005. SLC24A5, a putative cation exchanger, affects pigmentation in zebrafish and humans. Science 310:1782-1786. http://dx.doi.org/10.1126/science.1116238. (Pubitemid 41814374)
26. Adams KN, Takaki K, Connolly LE, Wiedenhoft Winglee K, Humbert O, Edelstein PH, Cosma CL, Ramakrishnan L. 2011. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell 145:39-53. http://dx.doi.org/10.1016/j.cell.2011.02.022.
27. Lavollay M, Fourgeaud M, Herrmann JL, Dubost L, Marie A, Gutmann L, Arthur M, Mainardi JL. 2011. The peptidoglycan of Mycobacterium abscessus is predominantly cross-linked by L,D-transpeptidases. J. Bacteriol. 193:778-782. http://dx.doi.org/10.1128/JB.00606-10.
28. Medjahed H, Reyrat JM. 2009. Construction of Mycobacterium abscessus defined glycopeptidolipid mutants: comparison of genetic tools. Appl. Environ. Microbiol. 75:1331-1338. http://dx.doi.org/10.1128/AEM.01914-08.
29. Howard ST, Rhoades E, Recht J, Pang X, Alsup A, Kolter R, Lyons CR, Byrd TF. 2006. Spontaneous reversion of Mycobacterium abscessus from a smooth to a rough morphotype is associated with reduced expression of glycopeptidolipid and reacquisition of an invasive phenotype. Microbiology 152:1581-1590. http://dx.doi.org/10.1099/mic.0.28625-0.
30. Zelmer A, Carroll P, Andreu N, Hagens K, Mahlo J, Redinger N, Robertson BD, Wiles S, Ward TH, Parish T, Ripoll J, Bancroft GJ, Schaible UE. 2012. A new in vivo model to test anti-tuberculosis drugs using fluorescence imaging. J. Antimicrob. Chemother. 67:1948-1960. http://dx.doi.org/10.1093/jac/dks161.
31. Andreu N, Zelmer A, Sampson SL, Ikeh M, Bancroft GJ, Schaible UE, Wiles S, Robertson BD. 2013. Rapid in vivo assessment of drug efficacy against Mycobacterium tuberculosis using an improved firefly luciferase. J. Antimicrob. Chemother. 68:2118-2127. http://dx.doi.org/10.1093/jac/dkt155.
32. Byrd TF, Lyons CR. 1999. Preliminary characterization of a Mycobacterium abscessus mutant in human and murine models of infection. Infect. Immun. 67:4700-4707. (Pubitemid 29400452)
33. Oh CT, Moon C, Jeong MS, Kwon SH, Jang J. 2013. Drosophila melanogaster model for Mycobacterium abscessus infection. Microbes Infect. 15:788-795. http://dx.doi.org/10.1016/j.micinf.2013.06.011.
34. Oh CT, Moon C, Park OK, Kwon SH, Jang J. 2014. Novel drug combination for Mycobacterium abscessus disease therapy identified in a Drosophila infection model. J. Antimicrob. Chemother. 69:1599-1607. http://dx.doi.org/10.1093/jac/ dku024.
35. Squiban B, Kurz CL. 2011. C. elegans: an all in one model for antimicrobial drug discovery. Curr. Drug Targets 12:967-977. http://dx.doi.org/10.2174/138945011795677854.
36. Takaki K, Cosma CL, Troll MA, Ramakrishnan L. 2012. An in vivo platform for rapid high-throughput antitubercular drug discovery. Cell Rep. 2:175-184. http://dx.doi.org/10.1016/j.celrep.2012.06.008.
37. Takaki K, Davis JM, Winglee K, Ramakrishnan L. 2013. Evaluation of the pathogenesis and treatment of Mycobacterium marinum infection in zebrafish. Nat. Protoc. 8:1114-1124. http://dx.doi.org/10.1038/nprot.2013.068.
38. Miyasaka T, Kunishima H, Komatsu M, Tamai K, Mitsutake K, Kanemitsu K, Ohisa Y, Yanagisawa H, Kaku M. 2007. In vitro efficacy of imipenem in combination with six antimicrobial agents against Mycobacterium abscessus. Int. J. Antimicrob. Agents 30:255-258. http://dx.doi.org/10.1016/j.ijantimicag.2007. 05.003. (Pubitemid 47126819)
39. Shen GH, Wu BD, Hu ST, Lin CF, Wu KM, Chen JH. 2010. High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria. Int. J. Antimicrob. Agents 35:400-404. http://dx.doi.org/10.1016/ j.ijantimicag.2009.12.008.
40. Phennicie RT, Sullivan MJ, Singer JT, Yoder JA, Kim CH. 2010. Specific resistance to Pseudomonas aeruginosa infection in zebrafish is mediated by the cystic fibrosis transmembrane conductance regulator. Infect. Immun. 78:4542-4550. http://dx.doi.org/10.1128/IAI.00302-10.
41. Bastian S, Veziris N, Roux AL, Brossier F, Gaillard JL, Jarlier V, Cambau E. 2011. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob. Agents Chemother. 55:775-781. http://dx.doi.org/10.1128/AAC.00861-10.
42. Kim HY, Kim BJ, Kook Y, Yun YJ, Shin JH, Kim BJ, Kook YH. 2010. Mycobacterium massiliense is differentiated from Mycobacterium abscessus and Mycobacterium bolletii by erythromycin ribosome methyltransferase gene (erm) and clarithromycin susceptibility patterns. Microbiol. Immunol. 54:347-353. http://dx.doi.org/10.1111/j.1348-0421.2010.00221.x.
43. Carvalho R, de Sonneville J, Stockhammer OW, Savage ND, Veneman WJ, Ottenhoff TH, Dirks RP, Meijer AH, Spaink HP. 2011. A high-throughput screen for tuberculosis progression. PLoS One 6:e16779. http://dx.doi.org/10.1371/journal. pone.0016779.
44. Spaink HP, Cui C, Wiweger MI, Jansen HJ, Veneman WJ, Marin-Juez R, de Sonneville J, Ordas A, Torraca V, van der Ent W, Leenders WP, Meijer AH, Snaar-Jagalska BE, Dirks RP. 2013. Robotic injection of zebrafish embryos for high-throughput screening in disease models. Methods 62:246-254. http://dx.doi.org/10.1016/j.ymeth.2013.06.002.